Korea Republic Of to India: Vaccine Import Trade Route
India has recorded 1 verified shipments of Vaccine imported from Korea Republic Of, representing a combined trade value of $60.7K USD. This corridor is served by 1 active Korea Republic Of exporters, with an average shipment value of $60.7K USD. The leading Korea Republic Of supplier is KBNP INC, which accounts for 100% of total import value with 1 shipments worth $60.7K USD. On the buying side, VIRBAC ANIMAL HEALTH INDIA PRIVATE LIMITED is the largest Indian importer with $60.7K USD in purchases. All data sourced from Indian Customs (DGFT) shipping bill of entry records. Values reported in FOB USD.
Route Intelligence Overview
The Korea Republic Of to India Vaccine corridor is one of India's established pharmaceutical import routes from Korea Republic Of, with 1 shipments documented worth a combined $60.7K USD. The route is dominated by KBNP INC, which alone accounts for roughly 100% of all import value, reflecting the consolidated nature of Korea Republic Of's vaccine export sector.
Across 1 active Korea Republic Of suppliers, the average shipment value stands at $60.7K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 80% of all shipments, consistent with vaccine's non-urgent bulk-order profile.
Shipment activity peaks during July–September, with an average transit time of 19 days port-to-port. The route has recorded an annual growth rate of 18.8%, placing it at rank #11 among India's top vaccine import origins globally.
On the Indian buyer side, key Indian importers include VIRBAC ANIMAL HEALTH INDIA PRIVATE LIMITED. VIRBAC ANIMAL HEALTH INDIA PRIVATE LIMITED is the single largest Indian importer with 1 shipments valued at $60.7K USD.
Route Characteristics
- Average transit19 days
- Peak seasonQ3
- Primary modeSea freight
- Top port of entryBombay Air Cargo
Market Position
- Global rank#11
- Annual growth+18.8%
- Demand growth+16.1%
- Regulatory ease84/100
Top 10 Vaccine Exporters from Korea Republic Of to India
Showing top 10 of 1 Korea Republic Of suppliers exporting Vaccine to India, ranked by total trade value (USD)
| Rank | Supplier (Korea Republic Of Exporter) | Shipments | Total Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | KBNP INC Avg $60.7K per shipment | 1 | $60.7K | 100.0% |
This table shows the top 10 of 1 Korea Republic Of companies exporting vaccine to India, ranked by total trade value. The listed exporters are: KBNP INC. KBNP INC is the dominant supplier with 1 shipments worth $60.7K USD, giving it a 100% market share.
Top 10 Indian Vaccine Importers from Korea Republic Of
Showing top 10 of 1 known Indian buyers receiving Vaccine shipments from Korea Republic Of, ranked by import value
On the receiving end of this trade route, the leading Indian importers of Korea Republic Of vaccine include VIRBAC ANIMAL HEALTH INDIA PRIVATE LIMITED. The largest importer is VIRBAC ANIMAL HEALTH INDIA PRIVATE LIMITED, accounting for $60.7K USD across 1 shipments — representing 100% of all vaccine imports from Korea Republic Of on this route.
| Rank | Indian Importer / Buyer | Shipments | Import Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | VIRBAC ANIMAL HEALTH INDIA PRIVATE LIMITED | 1 | $60.7K | 100.0% |
Top 10 Vaccine Formulations Imported from Korea Republic Of
Showing top 10 of 1 product formulations shipped on the Korea Republic Of to India Vaccine route, ranked by trade value
India imports a wide range of vaccine formulations from Korea Republic Of, spanning tablets, capsules, suspensions, and combination drugs. The top formulation — HIMMVAC DALGUBAN N PLUS LIVE VACCINE 2 000 D S HIMMVAC DALGUBAN N PLUS LIVE VACCINE 2 000 D S — accounts for $60.7K USD across 1 shipments. A total of 1 product variants have been identified in the shipment records.
| Rank | Product Formulation | Shipments | Trade Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | HIMMVAC DALGUBAN N PLUS LIVE VACCINE 2 000 D S HIMMVAC DALGUBAN N PLUS LIVE VACCINE 2 000 D S | 1 | $60.7K | 100.0% |
Shipping & Logistics Analysis
Freight mode split and port-of-origin breakdown
Freight Mode Distribution
Sea freight dominates at 80%, typical for bulk pharmaceutical shipments.
Top Indian Ports of Entry
Bombay Air Cargo handles the highest volume with 1 shipments. Transit time averages 19 days by sea.
Market Dynamics
India's vaccine imports from Korea Republic Of are driven primarily by a handful of large-scale Korea Republic Of manufacturers. KBNP INC with 1 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 1 active exporters signals a competitive but concentrated market — Indian buyers benefit from Korea Republic Of supplier diversity while the top tier handles the majority of volume.
The top 3 suppliers — KBNP INC — together account for 100% of total trade value on this route. The average shipment value of $60.7K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.
On the buying side, VIRBAC ANIMAL HEALTH INDIA PRIVATE LIMITED is the largest importer with 1 shipments worth $60.7K USD — representing 100% of all vaccine imports from Korea Republic Of on this route.
Route Statistics
- Trade Volume
- $60.7K
- Avg. Shipment
- $60.7K
- Suppliers
- 1
- Buyers
- 1
- Transit (Sea)
- ~19 days
- Annual Growth
- +18.8%
Other Vaccine Routes
Unlock the Full Korea Republic Of to India Vaccine Dataset
TransData Nexus provides verified shipment-level records, exporter contact details, HS code breakdowns, real-time pricing benchmarks, and regulatory compliance guides for 1 shipments on this route.
Frequently Asked Questions — Korea Republic Of to India Vaccine Trade
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which Korea Republic Of companies export Vaccine to India?
The leading Korea Republic Of exporters of Vaccine to India are KBNP INC. KBNP INC holds the largest market share at approximately 100% of total trade value on this route.
Q What is the total value of Vaccine imports from Korea Republic Of to India?
India imports Vaccine from Korea Republic Of worth approximately $60.7K USD across 1 recorded shipments. The average value per shipment is $60.7K USD.
Q Which Indian ports receive Vaccine from Korea Republic Of?
The most active Indian port of entry is Bombay Air Cargo with 1 shipments. Korea Republic Of exporters primarily use sea freight for this route, with 80% of shipments going by sea and 26% by air.
Q How long does shipping take from Korea Republic Of to India for Vaccine?
The average transit time for Vaccine shipments from Korea Republic Of to India is approximately 19 days. Sea freight typically takes longer, while air freight can reduce this significantly for urgent orders. Peak shipping activity is observed during July–September.
Q Is the Korea Republic Of to India Vaccine import route growing?
Yes — this trade corridor has seen an annual growth rate of approximately 18.8% with demand growth tracking at 16.1%. The route is ranked #11 among India's top Vaccine import origins globally.
Q How many Korea Republic Of suppliers are active on this Vaccine import route?
There are currently 1 active Korea Republic Of suppliers exporting Vaccine to India. The market is moderately concentrated with KBNP INC accounting for 100% of total shipment value.
Q Who are the main Indian importers of Vaccine from Korea Republic Of?
The leading Indian importers of Vaccine from Korea Republic Of include VIRBAC ANIMAL HEALTH INDIA PRIVATE LIMITED. VIRBAC ANIMAL HEALTH INDIA PRIVATE LIMITED is the largest buyer with 1 shipments worth $60.7K USD.
Official References & Regulatory Resources
- India Trade Statistics (DGFT)
- Invest India — Pharma Sector
- WCO HS Nomenclature
- Ministry of Commerce — Pharma Exports
- Pharmexcil
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Route Identification: India to Korea Republic Of export trade corridor identified from Indian Customs (DGFT) records for Vaccine.
- 2.Supplier/Buyer Matching: 1 Indian exporters and 1 importers in Korea Republic Of matched using name normalization.
- 3.Value Aggregation: Total export value aggregated from 1 verified shipping bill records. Values are FOB in USD.
- 4.Market Share Analysis: Each supplier and buyer contribution calculated as a percentage of total route value. Statistical normalization applied to ensure accurate representation across varying shipment sizes.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 Indian exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists